With more than $160 million under management, Birchmere Ventures has a successful track record of investing in and building early-stage technology and life sciences companies.

Philosophy: We focus principally on early stage, pre-revenue start-ups where we have direct operational or investing experience. We prefer to lead syndicated deals with other institutional investors. Industries that we target include:

» Advanced Technologies » Software » Communications » System components

» Drug discovery/improvement platforms » Biopharmaceuticals » Medical devices » Diagnostics

We also pursue convergent platforms where 
technology and life sciences intersect.

Board: To ensure that each of our companies gets the attention that it needs, we limit the number of board seats each partners holds. This strategy ensures that each company gets the attention it deserves.